Logo
x

Search

Subscribe Now

TG Therapeutics

TG Therapeutics Signs Ex-US Commercialization Agreement with Neuraxpharm for Briumvi (ublituximab-xiiy)

TG Therapeutics Signs Ex-US Commercialization Agreement with Neuraxpharm for Briumvi (ublituximab-xiiy)

  • August 1, 2023
Insights+: EMA Marketing Authorization of New Drugs in June 2023

Insights+: EMA Marketing Authorization of New Drugs in June 2023

  • July 29, 2023
TG Therapeutics’ Briumvi (ublituximab-xiiy) Receives EC’s Approval for the Treatment of Relapsing Forms of Multiple Sclerosis

TG Therapeutics’ Briumvi (ublituximab-xiiy) Receives EC’s Approval for the Treatment of Relapsing Forms of Multiple Sclerosis

  • June 2, 2023
TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis

TG Therapeutics Receives EMA’s CHMP Positive Opinion of Briumvi (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multipl...

  • March 31, 2023
TG Therapeutics’ Briumvi (ublituximab-xiiy) Receives the US FDA’s Approval for Relapsing Multiple Sclerosis

TG Therapeutics’ Briumvi (ublituximab-xiiy) Receives the US FDA’s Approval for Relapsing Multiple Sclerosis

  • December 29, 2022
TG Therapeutics Published P-III (ULTIMATE I & II) Trials Results of Ublituximab for RMS in the NEJM

TG Therapeutics Published P-III (ULTIMATE I & II) Trials Results of Ublituximab for RMS in the NEJM

  • August 26, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.